Using Chimeric Antigen Receptor Modified T-Cell to Treat B-Cell Leukemias

  • Ren Lian School New Jersey
  • Phyllis Arnold Rutgers Preparatory School
DOI: https://doi.org/10.18686/aem.v11i3.245
Keywords: Lymphocytic Leukemias, Cytotoxic T-Cells, CAR-T, CTL019

Abstract

Leukemias are cancers that happened in the blood of organisms, which affect the immune system’s T cells and B cells. Therefore, investigating studies to cure this disease are crucial. Several researchers demonstrated the use of modified receptors of T cells to fight leukemia. CTL019 (tisagenlecleucel) is a type of therapy that transplants the CD19 receptors into T cells to help them recognize the CD19+ B cells. They are used to detect and kill the cancerous B cell leukemia cells.  The chimeric antigen receptor-modified T-cell (CAR-T)  is a method that extracts the blood cells from the patients to cultivate the CD19 receptors. Finally, the blood would be injected back into the patients. Even though this method effectively kills CD19+ B-cells, it may have some side effects, such as the quick release of cytokines that can cause high systemic effects. With these side effects, scientists should investigate a better way to reduce the side effects in the future.

References

[1] Adlersberg JB., (1976). The immunoglobulin hinge (interdomain) region. Retrieved February 23, 2021.

[2] Cancer. net Leukemia-B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia - Statistics. (2021, January). Cancer.Net.

[3] Grupp SA, Kalos M, Barrett D, et al. (2013). Chimeric Antigen Receptor--Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine, 368(16), 1509–1518.

[4] Humphrey JH. and Perdue, SS (2020, August 20). Immune system. T cell antigen receptors Encyclopedia Britannica.

[5] Kalos M. Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds. Journal for ImmunoTherapy of Cancer 4, 5 (2016).

[6] Mayoclinic (2021, February 10). Acute lymphocytic leukemia. Retrieved February 23, 2021.

[7] Mayoclinic, (2019, April 03). Chronic lymphocytic leukemia. Retrieved February 23, 2021.

[8] Mayoclinic, (2021, January 13). Leukemia. Retrieved February 23, 2021.

[9] NCI Dictionary of Cancer TERMS. (n.d.). Retrieved February 23, 2021.

[10] Sharpe M. (2015, April 1). Genetically modified T cells in cancer therapy: opportunities and challenges, Disease Models & Mechanisms, The Company of Biologists. The Company of Biologists.

[11] Vairy S, Garcia JL, Teira P, & Bittencourt H. (2018). CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. Drug design, development and therapy, 12, 3885–3898.

[12] Wah M, Evelyn SDJ, Lynn TRC. (2014). Primer to the immune response. Chapter 8 Amsterdam: Elsevier.
Published
2022-11-03
Issue
Vol 11 No 3 (2022)
Section
Original Research Article

Copyright (c) 2022 Ren Lian

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.